Powered by OpenAIRE graph
Found an issue? Give us feedback

GETUG-AFU 25/PEACE 3: Personalized treatment of patients with metastatic castrate-resistant prostate cancer (MCRPC) receiving docetaxel, using either early switch to cabazitaxel or maintenance treatment with docetaxel plus radium-223, based on circulating tumor cell (CTCs) enumeration.

Funder: Institut National du CancerProject code: INCa-DGOS-7193 Call for proposal: PHRC13
Funded under: PHRC

GETUG-AFU 25/PEACE 3: Personalized treatment of patients with metastatic castrate-resistant prostate cancer (MCRPC) receiving docetaxel, using either early switch to cabazitaxel or maintenance treatment with docetaxel plus radium-223, based on circulating tumor cell (CTCs) enumeration.

Powered by OpenAIRE graph
Found an issue? Give us feedback

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

All Research products
arrow_drop_down
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::3ac9160c69db47d0007c56d558a7243b&type=result"></script>');
-->
</script>
For further information contact us at helpdesk@openaire.eu

No option selected
arrow_drop_down